癌症领域的共同研究及授权契约:2020～2025年

本报告全面深入分析了全球领先的生物製药公司签署的肿瘤学合作与许可协议，并提供前所未有的资讯取得管道。

本报告详细介绍了 2020 年至 2025 年间超过 3,000 项肿瘤领域的合作协议。

主要的优点

• 2016 年以来的交易趋势
• 肿瘤领域的合作与授权协议
• 透过基准分析确定市场价值
• 财务条款（预付款、里程碑付款、特许权使用费）
• 按公司、治疗领域和技术类型分类的合约目录
• 主要合约金额
• 最活跃的交易撮合者
• 查看每项协议的资产描述和条款
• 存取合约文件 - 深入了解合约结构
• 尽职调查 - 评估合作伙伴是否适合拟议条款
• 节省数百小时的研究时间

合约分析使您能够对…进行尽职调查以下：

• 具体授予或选择哪些权利？
• 协议具体授予合作伙伴哪些权利？
• 授予哪些独家经营权？
• 合约的付款结构是什么？
• 收入和付款将如何审计？
• 合约期限是多久？
• 合约的关键条款是如何定义的？
• 智慧财产权（IPR）将如何处理，所有权归谁？
• 谁负责商业化？
• 谁负责开发、供应和生产？
• 如何管理保密性和结果揭露？
• 如何解决争议？
• 在什么情况下可以终止合约？
• 如果公司所有权发生变更，合约将如何处理？
• 关于分授权和分包，双方约定的条款有哪些？
• 公司通常会包含哪些 "范本条款" ？
• 哪些 "范本条款" 会根据合约当事方和合约类型而有所不同？
• 公司要求以哪个司法管辖区（法院）作为合约法的适用法律？

目录

摘要整理

第1章 简介

第2章 癌症领域的契约动向

• 各年度的联盟趋势
• 各交易类型的联盟趋势
• 各产业部门的联盟趋势
• 各开发阶段的联盟趋势
• 各技术类型的联盟趋势
• 各治疗适应症的联盟趋势

第3章 癌症领域的财务条件分析

• 明确指示的财务条件
• 契约总额
• 预付款金
• 里程金
• 权利金费率

第4章 癌症领域:主要交易商与契约

• 最活跃的契约企业
• 最活跃的交易商清单
• 契约金额前几名的契约

第5章 癌症领域:契约文件的名录

• 可取得的联盟契约文件

第6章 癌症领域的契约:治疗标的

• 依治疗标靶划分的肿瘤学合约
• 合约目录
• 合约目录：依公司划分
• 合约目录：依技术类型划分
• 交易类型定义
• 关于 Biopharma Research Ltd
• 当前合作伙伴关係
• 当前协议
• 近期合作报告标题

Oncology Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the oncology deals entered into by the world's leading biopharma companies.

Fully revised and updated, the report provides details of 3,000+ oncology deals from 2020 to 2025.

The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of collaboration and licensing deals announced since 2020 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of oncology dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in oncology dealmaking.

Chapter 3 covers the financial deal terms for deals signed in the oncology field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.

Chapter 4 provides a review of the top 25 most active biopharma companies in oncology dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive and detailed review of oncology deals signed and announced since 2020 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of oncology deals listed by theraeutic target.

The report also includes numerous table and figures that illustrate the trends and activities in oncology deal making since 2020.

In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Oncology Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2020
• Browse oncology collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, therapy focus and technology type
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Oncology Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of oncology trends and structure of deals entered into by leading biopharma companies worldwide.

Oncology Collaboration and Licensing Deals includes:

• Trends in oncology dealmaking in the biopharma industry
• Overview of collaboration and licensing deal structure
• Directory of oncology deal records covering pharmaceutical and biotechnology
• The leading oncology deals by value
• Most active oncology licensing dealmakers

In Oncology Collaboration and Licensing Deals, the available deals are listed by:

• Company A-Z
• Headline value
• Therapeutic area
• Technology type
• Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
• Oncology Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in oncology dealmaking

• 2.1. Introduction
• 2.2. Oncology partnering over the years
• 2.3. Oncology partnering by deal type
• 2.4. Oncology partnering by industry sector
• 2.5. Oncology partnering by stage of development
• 2.6. Oncology partnering by technology type
• 2.7. Oncology partnering by therapeutic indication

Chapter 3 - Financial deal terms for oncology partnering

• 3.1. Introduction
• 3.2. Disclosed financials terms for oncology partnering
• 3.3. Oncology partnering headline values
• 3.4. Oncology deal upfront payments
• 3.5. Oncology deal milestone payments
• 3.6. Oncology royalty rates

Chapter 4 - Leading oncology deals and dealmakers

• 4.1. Introduction
• 4.2. Most active in oncology partnering
• 4.3. List of most active dealmakers in oncology
• 4.4. Top oncology deals by value

Chapter 5 - Oncology contract document directory

• 5.1. Introduction
• 5.2. Oncology partnering deals where contract document available

Chapter 6 - Oncology dealmaking by therapeutic target

• 6.1. Introduction
• 6.2. Deals by oncology therapeutic target
• Deal directory
• Deal directory - Oncology deals by company A-Z 2020 to 2025
• Deal directory - Oncology deals by technology type 2020 to 2025
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Oncology partnering since 2020
• Figure 2: Oncology partnering by deal type since 2020
• Figure 3: Oncology partnering by industry sector since 2020
• Figure 4: Oncology partnering by stage of development since 2020
• Figure 5: Oncology partnering by technology type since 2020
• Figure 6: Oncology partnering by indication since 2020
• Figure 7: Oncology deals with a headline value
• Figure 8: Oncology deals with upfront payment values
• Figure 9: Oncology deals with milestone payment
• Figure 10: Oncology deals with royalty rates
• Figure 11: Active oncology dealmaking activity since 2020
• Figure 12: Top oncology deals by value since 2020